Jingfeng Pharmaceutical(SZ:000908) Sou Hu Cai Jing·2025-08-04 08:21Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with a diverse product line including unique national insurance drugs and various injectable solutions [2]. Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.9 million yuan, representing a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of August 4, ST Jingfeng's stock closed at 5.94 yuan, down 1.16%, with a rolling price-to-earnings (PE) ratio of 36.92 times. The company's total market capitalization is 5.226 billion yuan [1]. - In comparison to the chemical pharmaceutical industry, which has an average PE ratio of 65.00 times and a median of 35.58 times, ST Jingfeng ranks 93rd in the industry [1][3]. Capital Flow - On August 4, the company experienced a net outflow of 3.8761 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 37.949 million yuan [1].